No Data
Genscript Biotech Divestment Gains Among Factors Supporting Results
GENSCRIPT BIO (01548.HK) profit alert: an anticipated significant increase in annual Net income compared to the same period last year.
Gelonghui reported on February 16 that GENSCRIPT BIO (01548.HK) announced that the group expects to achieve significant growth in Net income for the fiscal year ending December 31, 2024, compared to the fiscal year ending December 31, 2023. The expected increase in Net income is primarily attributed to the following reasons: (1) a one-time unrealized gain of approximately 3.2 billion USD from the sale of Legend Biotech. Legend Biotech Co., Ltd. ("Legend Biotech," whose shares are listed as American Depositary Shares on the Nasdaq Global Select Market in the USA) will be deconsolidated from the group effective October 18, 2024, and it will be reintroduced from that point on.
GENSCRIPT BIO: INSIDE INFORLATION: POSITIVE PROFIT ALERT
Trending Industry Today: WUXI BIO Leads Gains In Biotechnology Stocks
Trending Industry Today: TIGERMED Leads Gains In CRO Stocks
Hong Kong stocks fluctuated | CRO Concept stocks continued to surge in the morning, WUXI BIO (02269) and TIGERMED (03347) both rose over 9%.
In the early session, CRO Concept stocks continued to rise. As of the time of writing, WUXI BIO (02269) is up 9.59%, priced at 22.85 HKD; TIGERMED (03347) is up 9.09%, priced at 31.2 HKD; GENSCRIPT BIO (01548) is up 7.22%, priced at 11.88 HKD.
Genscript Biotech Corporation's (HKG:1548) P/S Is Still On The Mark Following 29% Share Price Bounce
